Craig Landau HS SM Color

Craig Landau, MD

President & Chief Executive Officer

Craig Landau, M.D. is the President and Chief Executive Officer for Purdue Pharma L.P. He is responsible for the company’s overall strategy and performance.

Craig started his career in the pharmaceutical industry in 1997 and joined Purdue Pharma L.P. in 1999. Prior to his most recent role as President and Chief Executive Officer of Purdue Pharma (Canada), which he still holds, he spent 14 years in leadership roles at Purdue Pharma L.P. in the United States. As Chief Medical Officer and Vice President of R&D Innovation, Clinical and Medical Affairs, Craig led a number of successful clinical development initiatives, resulting in analgesic product registrations in the U.S., Europe and other regions.

In April 2013, he played a lead role in the development and approval of reformulated OxyContin, a product determined by the U.S. Food and Drug Administration to possess abuse deterrent characteristics. And in 2016, Dr. Landau and Teva CEO, Doug Sommerville co-authored “Prescription Drug Abuse and Canada’s Lagging Regulatory Framework.

Craig earned his B.Sc. in Physiology and Anatomy from Cornell University and his M.D. from Mount Sinai School of Medicine. He completed his Anesthesiology residency at Yale University, with specialty training in chronic pain management, obstetric and peripheral vascular anesthesia. Dr. Landau is also a U.S. Army Veteran, concluding his 14-years of distinguished service in 2005.

Leadership page

The prescription and illicit opioid abuse crisis is a multifaceted public health challenge, and as a manufacturer of prescription opioids, we have a responsibility to join the fight. At Purdue we are committed to lead our industry in helping address our nation's prescription and illicit opioid abuse crisis.

There is more to come – as we continue to work with partners and experts to deliver solutions. Below you will find additional information about our efforts.

Read our open letter about the opioid crisis.